Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;198(4):780-784.
doi: 10.1111/bjh.18290. Epub 2022 May 26.

Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia

Alexis Genthon  1 , Diana Dragoi  1 , Mara Memoli  1 , Pierre Hirsch  2 , Fabrizia Favale  2 , Ludovic Suner  2 , Michael Chaquin  2 , Pierre Boncoeur  2 , Zora Marjanovic  1 , Agnès Bonnin  1 , Simona Sestili  1 , Remy Dulery  1 , Florent Malard  1 , Eolia Brissot  1 , Anne Banet  1 , Zoe van de Wyngaert  1 , Anne Vekhoff  1 , Francois Delhommeau  2 , Mohamad Mohty  1 , Ollivier Legrand  1
Affiliations

Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia

Alexis Genthon et al. Br J Haematol. 2022 Aug.
No abstract available

Keywords: AML; IDH; allo-SCT; enasidenib; ivosidenib.

PubMed Disclaimer

References

REFERENCES

    1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47.
    1. Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V, et al. Allogeneic transplantation for advanced acute myeloid leukemia: the value of complete remission. Cancer. 2017;123(11):2025-34.
    1. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J Clin Oncol. 2012;30(20):2492-9.
    1. Cucchi DGJ, Polak TB, Ossenkoppele GJ, Uyl-De Groot CA, Cloos J, Zweegman S, et al. Two decades of targeted therapies in acute myeloid leukemia. Leukemia. 2021;35(3):651-60.
    1. Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol Lond Engl. 2018;14(10):979-93.

Publication types

MeSH terms

LinkOut - more resources